NAD+observational2018

NAD+ as a Hydride Donor and Reductant.

Journal of the American Chemical Society

confidence

Key findings

NAD+ can function as a reductant and hydride donor via beta-hydride elimination from a ribose subunit, forming a Ru-H intermediate; no clinical/biological endpoints reported.

View source on PubMed (PMID 27960347) ↗

Population
In vitro (chemical study)
Blinding
not_reported
Controls
none
Drug class
coenzyme
Full abstract

Reduced nicotinamide adenine dinucleotide (NADH) can generate a ruthenium-hydride intermediate that catalyzes the reduction of O2 to H2O2, which endows it with potent anticancer properties. A catalyst that could access a Ru-H intermediate using oxidized nicotinamide adenine dinucleotide (NAD+) as the H- source, however, could draw upon a supply of reducing equivalents 1000-fold more abundant than NADH, which would enable significantly greater H2O2 production. Herein, it is demonstrated, using the reduction of ABTS•- to ABTS2-, that NAD+ can function as a reductant. Mechanistic evidence is presented that suggests a Ru-H intermediate is formed via β-hydride elimination from a ribose subunit in NAD+. The insight gained from the heretofore unknown ability of NAD+ to function as a reductant and H- donor may lead to undiscovered biological carbohydrate oxidation pathways and new chemotherapeutic strategies.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.